Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease.
predictive marker
rituximab
surfactant protein-D
systemic sclerosis
systemic sclerosis-associated interstitial lung disease
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
02
02
2020
accepted:
09
04
2020
pubmed:
10
5
2020
medline:
15
5
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
Systemic sclerosis (SSc) is an autoimmune disorder characterized by vascular damage and excessive fibrosis. SSc-associated interstitial lung disease (ILD) is a leading cause of death in SSc. Several studies have shown the efficacy of rituximab (RTX) in SSc-ILD, but no study has examined the relation between RTX reactivity and change of serum marker levels. In this study we examined the relation between change of serum surfactant protein-D (SP-D) levels and change of percentage forced vital capacity (FVC) in 11 SSc-ILD patients with anti-topoisomerase I antibody treated by RTX. Serum SP-D levels were significantly decreased compared with baseline at 2 weeks after first RTX infusion in good responders (P = 0.04), while not in poor responders (P = 0.77). Moreover, ΔSP-D at 2 weeks negatively correlated with Δ%FVC at 24 weeks (P = 0.001). In conclusion, we suggested that the rapid decrease of SP-D levels may be a predictive marker of RTX effect against SSc-ILD.
Identifiants
pubmed: 32383266
doi: 10.1111/1346-8138.15379
doi:
Substances chimiques
Pulmonary Surfactant-Associated Protein D
0
Surface-Active Agents
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
796-800Informations de copyright
© 2020 Japanese Dermatological Association.
Références
LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815.
Caldas MMVF, Neto FAB, Azevedo KPM, Pimenta IDSF, Oliveira AKDSG, Piuvezam G. Rituximab in systemic sclerosis: a protocol for systematic review. Medicine 2019; 98: e17110.
Bonhomme O, André B, Gester F et al. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology 2019; 58: 1534-1546.
Sumida H, Asano Y, Tamaki Z et al. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: a longitudinal observational study. J Dermatol 2018; 45: 1425-1433.
van den Hoogen F, Khanna D, Fransen J et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-1755.
Clements P, Lachenbruch P, Siebold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-1285.
Khanna D, Tseng CH, Furst DE et al. Minimally important differences in the Mahler’s Transition Dyspnoea Index in a large randomized controlled trial-results from the Scleroderma Lung Study. Rheumatology 2009; 48: 1537-1540.
Daoussis D, Tsamandas A, Antonopoulos I et al. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 2016; 18: 118.
Fujimoto M, Sato S. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 2005; 17: 746-751.
Ebata S, Yoshizaki A, Fukasawa T et al. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. J Dermatol 2019; 46: 1006-1013.
Takahashi H, Fujishima T, Koba H et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 2000; 162: 1109-1114.
Yamakawa H, Hagiwara E, Kitamura H et al. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease. J Thorac Dis 2017; 9: 362-371.
Ikeda K, Shiratori M, Chiba H et al. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Med 2017; 131: 184-191.